REFERENCES
1. Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol Off J Eur Soc Med Oncol2012;23 Suppl 8 :viii6-9.
2. Cervantes-Villagrana RD, Albores-García D, Cervantes-Villagrana AR, García-Acevez SJ. Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies. Signal Transduct Target Ther 2020;5 :99.
3. Carretero R, Sektioglu IM, Garbi N, Salgado OC, Beckhove P, Hämmerling GJ. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol 2015;16 :609–617.
4. Ellis GI, Riley JL. How to kill Treg cells for immunotherapy.Nat Cancer 2020;1 :1134–1135.
5. Labanieh L, Majzner RG, Mackall CL. Programming CAR-T cells to kill cancer. Nat Biomed Eng 2018;2 :377–391.
6. De Bock K, Mazzone M, Carmeliet P. Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? Nat Rev Clin Oncol2011;8 :393–404.
7. Liu M, Kuo F, Capistrano KJ, Kang D, Nixon BG, Shi W et al. TGF-β suppresses type 2 immunity to cancer. Nature2020;587 :115–120.
8. Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease.Nat Rev Drug Discov 2016;15 :35–50.
9. Ye Y, Hu Q, Chen H, Liang K, Yuan Y, Xiang Y et al. Characterization of Hypoxia-associated Molecular Features to Aid Hypoxia-Targeted Therapy. Nat Metab 2019;1 :431–444.
10. Donato C, Kunz L, Castro-Giner F, Paasinen-Sohns A, Strittmatter K, Szczerba BM et al. Hypoxia Triggers the Intravasation of Clustered Circulating Tumor Cells. Cell Rep 2020;32 :108105.